Literature DB >> 6999983

Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin.

T Nishi, K Tsuchiya.   

Abstract

Such factors as suspending medium, operating pressure, exposure time, inoculum size, and strain, sex, age, and weight of the animals were examined for their effects on the development of respiratory tract infection with Klebsiella pneumoniae DT-S in mice. The suspending medium was one of the most important factors. Aerosol challenge with a 10(9) colony-forming units per ml resulted in deposition of 10(4) colony-forming units of the organisms in the lung. The numbers of organisms in the lung increased rapidly, and by 30 h, a well-developed pneumonia was apparent. All the mice died within 4 days after infection. The therapeutic effectiveness of single-dose kanamycin regimens decreased markedly with a delay in administration. The effectiveness of multi-dose kanamycin regimens was influenced by the frequency of dosage. Thus a 12-h dosage schedule was superior to a 24-h regimen. Administration of 20 mg of kanamycin per kg at 12-h intervals for 10 days, initiated 30 h after infection, provided a complete cure. The infecting organisms in the lung, trachea, and blood were eradicated by the kanamycin therapy, but those in the nasal cavity were difficult to eliminate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6999983      PMCID: PMC283816          DOI: 10.1128/AAC.17.3.494

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Treatment of respiratory Klebsiella pneumoniae infection in mice with aerosols of kanamycin.

Authors:  R F Berendt; G G Long; J S Walker
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

2.  A QUANTITATIVE STUDY OF THE DEPOSITION AND CLEARANCE OF BACTERIA IN THE MURINE LUNG.

Authors:  G A LAURENZI; L BERMAN; M FIRST; E H KASS
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

3.  Experimental anthrax in the rat. I. The rapid increase of natural resistance observed in young hosts.

Authors:  M J TAYLOR; G H KENNEDY; G P BUNDELL
Journal:  Am J Pathol       Date:  1961-04       Impact factor: 4.307

4.  Genetic effects in nonspecific resistance to infectious disease.

Authors:  J W GOWEN
Journal:  Bacteriol Rev       Date:  1960-03

5.  The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia.

Authors:  L H SCHMIDT; A WALLEY
Journal:  J Pharmacol Exp Ther       Date:  1951-12       Impact factor: 4.030

6.  Pulmonary infection due to disruption of the pharyngeal bacterial flora by antibiotics in hamsters.

Authors:  H P Dalton; M Muhovich; M R Escobar; M J Allison
Journal:  Am J Pathol       Date:  1974-09       Impact factor: 4.307

7.  Microbiology of nosocomial infections.

Authors:  V Lorian; B Topf
Journal:  Arch Intern Med       Date:  1972-07

8.  Effect of nitrogen dioxide on resistance to respiratory infection.

Authors:  R Ehrlich
Journal:  Bacteriol Rev       Date:  1966-09

9.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

10.  Quantitative nasal cultures from carriers of Staphylococcus aureus: effects of oral therapy with erythromycin, rosamicin, and placebo.

Authors:  S Z Wilson; R R Martin; M Putman; S B Greenberg; R J Wallace; J G Jemsek
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more
  9 in total

1.  Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice.

Authors:  T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

2.  Application of mathematical model to experimental chemotherapy of fatal murine pneumonia.

Authors:  T Hishikawa; T Kusunoki; K Tsuchiya; Y Uzuka; T Sakamoto; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

3.  Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.

Authors:  Y Iizawa; K Okonogi; R Hayashi; T Iwahi; T Yamazaki; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

5.  Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.

Authors:  N Klesel; M Limbert; G Seibert; I Winkler; E Schrinner
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.

Authors:  H Wakebe; T Imada; H Yoneda; F Mukai; K Ohguro; K Ohmori; H Tamaoka; Y Yabuuchi
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  In vitro and in vivo morphological response of Klebsiella pneumoniae to cefotiam and cefazolin.

Authors:  M Nakao; T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; M Kida; M Nakao; T Iwahi; T Nishi; Y Noji; M Takeuchi; Y Nozaki
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.